Summary: The use of molecular virology is described. Emphasis is placed on molecular biology, especially methods involving gene technology. The respective techniques allow characterisation of viruses by molecular cloning and nucleotide sequencing as well as the development of new diagnostic tools and vaccines. Genetically engineered live viruses serve as examples to study potential risks of vaccines derived from such viruses.
Biotechnology covers a wealth of specialised disciplines which include not only the new genetic engineering techniques but also old foundation processes which our ancestors practised thousands of years ago, for example fermentation by yeast. In general, biotechnology means the use of biological systems for production of substances. Therefore, production, isolation, engineering and use of substances derived from biosynthesis are parts of biotechnology (3) .
In the last 15-20 years, many exciting developments concerning biotechnical methods have taken place, and the field has gained greatly in importance. Substantial progress in the biological sciences, especially in microbiology, biochemistry and molecular biology, allow a more efficient control of viral animal diseases. It seems very likely that biotechnology, especially gene technology, will continue to be of great significance for veterinary medicine including virology (2) .
At the Federal Research Centre for Virus Diseases of Animals in Tübingen, the following major research projects are in progress: a) development and improvement of vaccines b) preparation and improvement of diagnostic procedures c) investigation of the pathogenesis, and defence against viral diseases in animals d) execution of measures against epidemics caused by animal viruses.
Besides conventional virological and serological methods, recently developed techniques of molecular biology, in particular gene technology and immunology, are employed.
In the following we will describe the use of molecular virology at our Institute. In this context, emphasis is placed on molecular biology, especially methods involving gene technology, while monoclonal antibodies will be briefly discussed. Finally, genetically engineered live viruses serve as examples to study potential risks of vaccines derived from such viruses.
Characterisation of viruses by molecular cloning
Until the advent of molecular biology, viruses were characterised primarily by physical and biochemical methods, including parameters like size, density, protein composition and nucleic acid (DNA or RNA, single-stranded or double-stranded). The genome was studied only with regard to size, kind of nucleic acid (DNA or RNA, single-stranded or double-stranded, positive or negative polarity) and base composition. The methods of gene technology permitted cloning of the viral genome and thus characterisation of genes, as well as manipulation of a viral genome (4) . A molecularly cloned virus is a well-defined entity, especially in comparison with a given virus stock.
Without the techniques of molecular biology, difficult virus systems like pestiviruses (9) and hepadnaviruses (7) were and are almost impossible to attack. This is well documented in publications of the past thirty years. It is now possible to apply this knowledge directly to study pathogenesis and even vaccine development, as the example of hepatitis B has shown.
Development of new diagnostic tools
Conventional serology for diagnosis of viral infections involves mostly the use of polyspecific antisera in assays like complement fixation, agar gel diffusion, immunofluorescence and haemagglutination. Recently these antisera have been almost completely replaced by well-defined monospecific antisera or monoclonal antibodies. In addition, the range of techniques has been widened by introduction of radioimmunoassay, immune electron microscopy, enzyme immunoassay and the Western blot technique (8) .
For example, diagnosis of foot and mouth disease was accomplished by complement fixation (CF) with a variety of hyperimmune polyspecific guinea-pig sera. A collection of monoclonal antibodies can now be used rapidly to identify not only the serotype, but also the subtype. In addition, the ELISA technique has replaced CF.
Further analysis of isolated FMDV can be performed by nucleic acid analysis. For this, the viral RNA is reverse transcribed and sequenced by standard techniques. This provides information on the nucleotide sequence and deduced amino acid sequence of the coat proteins on the most accurate basis possible. Thus the origin of an FMD outbreak can be traced, especially if such an outbreak is due to incompletely inactivated vaccine or to an institute which handles infectious FMDV (5).
Vaccines
Conventional vaccines comprise virulent viruses, which have been inactivated by various methods including formaldehyde and ethylenimine. Alternatively, live viruses have been attenuated, usually by multiple passages in xenogeneic hosts. Until recently, the molecular basis for virus attenuation was totally unclear.
Major efforts are now directed towards understanding the basic differences between attenuated and virulent virus. In the case of Pseudorabies virus (PRV), a herpesvirus, at least one virulence gene, namely gI, has been clearly identified. It has been shown that this gene is deleted in many PRV vaccine strains (11). This has made it possible to develop a new strategy for immunisation against PRV: only gI-negative strains will be used for vaccination in many countries, thus allowing differentiation from wild type virus by a simple serological test.
Nucleic acid sequence comparisons between polio virus wild type and attenuated virus (Sabin strain) have revealed very few point mutations, which make reversion of vaccine virus to virulent virus possible (1). In the case of classical swine fever virus, we hope to discover differences between attenuated and virulent strains on a molecular basis.
From the above it is clear that molecular virology will make it possible to create attenuated viruses by manipulating the cloned genome. This will ensure that reversion cannot occur. Such a vaccine can be based on the original virus or relevant genes (whose products lead to a protective immune response), and it can be placed under control of a virus vector system, for example vaccinia virus (10) .
As an alternative, relevant regions of the viral genome can be expressed in various systems, for example E. coli, yeast, baculovirus or other eukaryotic expression systems. The purified gene product will be used for immunising the relevant host. Experimentally it has even been shown that rather small synthetic peptides derived from a single FMDV coat protein can lead to a protective immune response (12) . Such subunit vaccines and synthetic peptides are not yet as effective as live virus vaccines. It is, however, worthwhile to continue studies of these kinds of vaccines, since there is almost no risk involved in production and application.
Risks involved with release of genetically manipulated organisms
Certain aspects of biotechnology, especially gene technology, are being intensely discussed among scientists and in public. It is important to differentiate between potential risks that could be present in the laboratory, and the risks associated with release of genetically manipulated micro-organisms. We think that the former have been handled adequately with regard to the safety conditions worked out by the "Zentrale Kommission für Biologische Sicherheit" (ZKBS) (6).
Any release of genetically manipulated micro-organisms should be preceded by basic experiments. Such a project was recently established at the Federal Research Centre for Virus Diseases of Animals. As a first step, marker gene(s) and/or unique restriction sites are introduced into the construct to make identification unambiguous. Thereafter, animal experiments have to be conducted to find out whether:
1. the recombinant virus is a safe and effective vaccine 2. recombination occurs with the respective wild type virus 3. a potential recombinant is more pathogenic than the wild type 4. changes occur in the host range.
This list is certainly incomplete and additional criteria are being examined, for example by the United States Department of Agriculture (USDA). After performing these experiments, a limited and controlled field study should be conducted. For example, in the USA it is planned to conduct such a study on two islands, using a raccoon vaccinia construct which contains the rabies glycoprotein gene.
In summary, recent aspects of biotechnology, especially recombinant DNA research, hold great promise, and modern molecular virology is unthinkable now without these techniques. It is almost ridiculous that some persons have such strong reservations against future genetically engineered vaccines, because these vaccines would be well defined, effective and safer than those currently available (13) . It is obvious that conventional live attenuated viruses which have been used widely in human medicine can be compared with the respective wild type only by molecular biology techniques. For example, such techniques have revealed very subtle differences in polio virus vaccine, such that reversion to the wild type can easily occur. We are convinced that vaccine development using recombinant DNA techniques can do better than that. Resumen: Los autores describen la virología molecular y subrayan el papel de la biología molecular, en particular de los métodos que recurren a la tecnología genética. Estas técnicas permiten caracterizar virus por clonación molecular y determinación de secuencias de nucleótidos, así como el desarrollo de nuevos medios de diagnóstico y de nuevas vacunas. Los virus vivos obtenidos a partir de técnicas de ingeniería genética sirven de ejemplos para el estudio de los riesgos potenciales de las vacunas derivadas de ellos.
